Navigation Links
Medizone International Announces Third Round of AsepticSure

SAN FRANCISCO, Oct. 14 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) announces that a third round of AsepticSure(TM) trials have begun at Innovation Park, Queen's University. Building on the results obtained during the first and second round of laboratory testing, this third round is being conducted to establish the precise protocols necessary in order to obtain maximum bactericidal action in combination with minimum turn-around times in keeping with normal hospital flow patterns. Simultaneously, a development prototype is being finalized in order to conduct a full room scale hospital mock up.

Medizone's CEO Edwin Marshall stated, "While this stage of the development program has taken a bit longer than we envisioned, we expect the results to be well worthwhile. It is now clear the integration of technology involved, combined with the scientific data that continues to be gathered, should not only establish Medizone's AsepticSure(TM) system as the global standard for hospital and infrastructure decontamination, but with additional state of the art interlocking patent opportunities being developed, should offer the company exceedingly strong patent protection for this emerging technology."

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. The trial program has been expanded in final preparation for a hospital mock-up, intended to be followed by hospital beta testing. It is estimated hospitals deploying the AsepticSure(TM) system will save $6 to $7 for each $1 invested while preventing tens of thousands of hospital acquired infections.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

           Investor Relations: 415-868-0300 / web site:

SOURCE Medizone International, Inc.

SOURCE Medizone International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
4. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
7. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
8. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
Post Your Comments:
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
(Date:11/30/2015)... -- North America was valued at ... a CAGR of 7.6% from 2015 to 2020. --> ... in 2014, and is expected to grow at a CAGR of ... new Market Research Report "North America Cardiac Output Monitoring Devices Market ... care, others) - Analysis And Forecast To 2020", the cardiac output ...
(Date:11/30/2015)... 30, 2015  Kevin Smith has been appointed ... global pioneer in wireless monitoring of vital signs.  ... , Mr. Smith will be responsible for ... strategy.  He will also directly oversee partnering with ... evidence for SensiumVitals, the first early warning detection ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Beard and Brooke Bennett are collaborating with brands across various categories through traditional ... influential figures make up an elite group of Gold Medal Moms who can ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. She ... is the nation’s leading networking organization exclusively for professional women, boasting more than 850,000 ...
(Date:11/30/2015)... ... 2015 , ... Being a caregiver for someone you love ... Care System, the Caregiver Support Program promotes the health and wellbeing of family ... percent report that their role as a caregiver has created marital strain,” said ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to research by ... require dental technicians to be certified or obtain continuing education. To increase awareness ... In Your Mouth?” campaign to inform dentists that the technicians they trust could ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Museum of Science & ... a new era of publicly accessible automated technology. Now, by popular demand, the ... guests an up-close look at the shuttle at MOSI’s main entrance. This experience ...
Breaking Medicine News(10 mins):